FKBP10 and neoplasm: To further explore the tumorigenic capacity of FKBP10 in ccRCC, we used cell lines derived xenograft (CDX) model subcutaneously injected with RENCA cells (Fig. 2G, H and S2M), which showed that FKBP10 knockdown or overexpressed could inhibit or promote tumor growth in vivo.